PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652

被引:12
作者
Liu, Yuncheng [1 ]
Peng, Yuan [2 ]
Du, Wei [2 ]
Yu, Chunyu [3 ]
Peng, Zijun [1 ]
Qin, Leyi [1 ]
Ma, Yilei [1 ]
Wu, Xin [1 ]
Peng, Yani [1 ]
Cheng, Xiao [1 ]
Xia, Lu [1 ]
Fa, Hangwei [1 ]
Wu, Yuqing [1 ]
Sun, Luyang [1 ]
Liu, Jianying [4 ]
Liu, Zhihua [5 ]
Shang, Yongfeng [1 ,3 ,6 ]
Wang, Shu [2 ]
Liang, Jing [1 ]
机构
[1] Peking Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res,Minist Educ,, Beijing 100191, Peoples R China
[2] Peking Univ Peoples Hosp, Breast Dis Ctr, Beijing 100044, Peoples R China
[3] Hangzhou Normal Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Hangzhou 311121, Peoples R China
[4] Peking Univ, Sch Basic Med Sci, Dept Pathol, Hlth Sci Ctr, Beijing 100191, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, State Key Lab Mol Oncol, Natl Clin Res Ctr Canc,Natl Canc Ctr, Beijing 100021, Peoples R China
[6] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing 100069, Peoples R China
基金
中国国家自然科学基金;
关键词
ZINC-FINGER PROTEIN; UP-REGULATION; PD-L1; EXPRESSION; RECEPTOR; ZNF652; TRANSCRIPTION; CARCINOMAS; ESCAPE;
D O I
10.1016/j.celrep.2023.113343
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The intrinsic regulation of programmed death ligand-1 (PD-L1) expression remains unclear. Here, we report that zinc-finger protein 652 (ZNF652) is a potent transcription repressor of PD-L1. ZNF652 frequently experiences loss of heterozygosity (LOH) in various cancers. Higher LOH rate and lack of estrogen-inducible transcription lead to suppressed expression of ZNF652 in triple-negative breast cancer (TNBC). Mechanistically, ZNF652 is physically associated with the NuRD transcription co-repressor complex to repress a cohort of genes, including PD-L1. Overexpression of ZNF652 inhibits PD-L1 transcription, whereas depletion of ZNF652 upregulates PD-L1. Loss of ZNF652 in TNBC unleashes PD-L1-mediated immune evasion both in vitro and in vivo. Significantly, ZNF652 expression is progressively lost during breast cancer progression, and a low ZNF652 level is correlated with elevated PD-L1 expression, less infiltrated CD8+ T cells, and poor prognosis in TNBC. Our study provides insights into PD-L1 regulation and supports the pursuit of ZNF652 as a potential biomarker and drug target for breast cancer immunotherapy.
引用
收藏
页数:25
相关论文
共 40 条
[1]   Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].
Akbay, Esra A. ;
Koyama, Shohei ;
Carretero, Julian ;
Altabef, Abigail ;
Tchaicha, Jeremy H. ;
Christensen, Camilla L. ;
Mikse, Oliver R. ;
Cherniack, Andrew D. ;
Beauchamp, Ellen M. ;
Pugh, Trevor J. ;
Wilkerson, Matthew D. ;
Fecci, Peter E. ;
Butaney, Mohit ;
Reibel, Jacob B. ;
Soucheray, Margaret ;
Cohoon, Travis J. ;
Janne, Pasi A. ;
Meyerson, Matthew ;
Hayes, D. Neil ;
Shapiro, Geoffrey I. ;
Shimamura, Takeshi ;
Sholl, Lynette M. ;
Rodig, Scott J. ;
Freeman, Gordon J. ;
Hammerman, Peter S. ;
Dranoff, Glenn ;
Wong, Kwok-Kin .
CANCER DISCOVERY, 2013, 3 (12) :1355-1363
[2]   Molecular determinants of response to PD-L1 blockade across tumor types [J].
Banchereau, Romain ;
Leng, Ning ;
Zill, Oliver ;
Sokol, Ethan ;
Liu, Gengbo ;
Pavlick, Dean ;
Maund, Sophia ;
Liu, Li-Fen ;
Kadel, Edward, III ;
Baldwin, Nicole ;
Jhunjhunwala, Suchit ;
Nickles, Dorothee ;
Assaf, Zoe June ;
Bower, Daniel ;
Patil, Namrata ;
McCleland, Mark ;
Shames, David ;
Molinero, Luciana ;
Huseni, Mahrukh ;
Sanjabi, Shomyseh ;
Cummings, Craig ;
Mellman, Ira ;
Mariathasan, Sanjeev ;
Hegde, Priti ;
Powles, Thomas .
NATURE COMMUNICATIONS, 2021, 12 (01)
[3]   Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome [J].
Callen, David F. ;
Ricciardelli, Carmela ;
Butler, Miriam ;
Stapleton, Alan ;
Stahl, Jurgen ;
Kench, James G. ;
Horsfall, David J. ;
Tilley, Wayne D. ;
Schulz, Renee ;
Nesland, Jahn M. ;
Neilsen, Paul M. ;
Kumar, Raman ;
Holm, Ruth .
ONCOLOGY REPORTS, 2010, 23 (04) :1045-1052
[4]   MYC regulates the antitumor immune response through CD47 and PD-L1 [J].
Casey, Stephanie C. ;
Tong, Ling ;
Li, Yulin ;
Do, Rachel ;
Walz, Susanne ;
Fitzgerald, Kelly N. ;
Gouw, Arvin M. ;
Baylot, Virginie ;
Guetgemann, Ines ;
Eilers, Martin ;
Felsher, Dean W. .
SCIENCE, 2016, 352 (6282) :227-231
[5]   Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma [J].
Clark, Curtis A. ;
Gupta, Harshita B. ;
Sareddy, Gangadhara ;
Pandeswara, Srilakshmi ;
Lao, Shunhua ;
Yuan, Bin ;
Drerup, Justin M. ;
Padron, Alvaro ;
Conejo-Garcia, Jose ;
Murthy, Kruthi ;
Liu, Yang ;
Turk, Mary Jo ;
Thedieck, Kathrin ;
Hurez, Vincent ;
Li, Rong ;
Vadlamudi, Ratna ;
Curiel, Tyler J. .
CANCER RESEARCH, 2016, 76 (23) :6964-6974
[6]   HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy [J].
Deng, Siyu ;
Hu, Qianwen ;
Zhang, Heng ;
Yang, Fang ;
Peng, Cheng ;
Huang, Chuanxin .
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) :900-908
[7]  
Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
[8]   Immunotherapy Approaches for Breast Cancer Patients in 2023 [J].
Emens, Leisha A. ;
Loi, Sherene .
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2023, 13 (04)
[9]   Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells [J].
Feng, J. ;
Yang, H. ;
Zhang, Y. ;
Wei, H. ;
Zhu, Z. ;
Zhu, B. ;
Yang, M. ;
Cao, W. ;
Wang, L. ;
Wu, Z. .
ONCOGENE, 2017, 36 (42) :5829-5839
[10]   Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].
Freeman, GJ ;
Long, AJ ;
Iwai, Y ;
Bourque, K ;
Chernova, T ;
Nishimura, H ;
Fitz, LJ ;
Malenkovich, N ;
Okazaki, T ;
Byrne, MC ;
Horton, HF ;
Fouser, L ;
Carter, L ;
Ling, V ;
Bowman, MR ;
Carreno, BM ;
Collins, M ;
Wood, CR ;
Honjo, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034